HEALTH POLICY BRIEF — Friday, July 24

Executive Briefing

Three developments meet this publication’s coverage focus this morning. ONC finalized USCDI v7 and immediately opened the v8 input window; FDA and the CMS Innovation Center put the first manufacturer into their joint digital-health evidence and payment test bed; and HHS rewrote its Title VI enforcement rules for federally funded health care. The first two create concrete standards and physician-led AI governance work. The third warrants careful legal monitoring, not sweeping compliance conclusions.

Standards / Coding / Data Infrastructure

ONC finalizes USCDI v7; v8 submissions are due September 28. The July 23 release adds 30 data elements and significantly revises one, including referral orders and notes, appointments, device orders, imaging references, reason-not-performed, adverse-event data, and specimen collection date/time. Fifteen of the additions or changes are already represented in required implementation specifications and are largely supported by certified health IT.

Policy relevance: ONC finished a content standard; it did not flip a compliance switch. USCDI v7 is not the version approved in the 2026 SVAP—v6 is—so there is no immediate v7 certification mandate or provider implementation deadline. The actionable development is ONC’s new USCDI v8 submission and comment period, open through September 28 at 11:59 p.m. ET.

Physician policy angle: The near-term action is standards input, not an EHR upgrade. Review final v7 against prior physician comments, identify v8 proposals, and press vendors to map existing LIS/EHR data rather than create new manual entry, reconciliation, training, or alert work. Small practices will otherwise inherit whatever their vendor contract and release schedule decide to hand them. ONC Standards Bulletin 2026-2 (https://healthit.gov/standards-and-technology/onc-standards-bulletin/onc-standards-bulletin-2026-2/)

Digital Health / AI / Privacy / Cyber / Interoperability

FDA selects Dexcom as the first TEMPO participant tied to CMMI’s ACCESS model. FDA’s July 22 selection covers the Dexcom Glucose Health Program, which is intended to support metabolic and nutritional monitoring, tailored guidance, and real-time data and AI insights for prediabetes and type 2 diabetes use cases. The manufacturer will generate real-world performance data while ACCESS tests recurring, outcome-aligned Medicare payments for technology-supported chronic care.

Policy relevance: This is a regulatory-payment test bed, not national coverage or a clearance. FDA selection is not marketing authorization, does not establish a new NCD or LCD, and creates no general duty for nonparticipants or referring practices. Referring clinicians may choose to review structured care updates and document coordination; CMS currently pays $30 per service, plus a one-time $10 onboarding modifier, up to three times per patient, track, and year.

Physician policy angle: The policy work starts before the workflow hardens. Seek algorithm transparency, data provenance, human escalation rules, clear liability boundaries, interoperable update formats, privacy and cybersecurity safeguards, and evidence that the co-management payment covers the reconciliation and documentation being requested. Do not let “technology-enabled care” become another elegant federal phrase for unpaid inbox work. FDA TEMPO announcement (https://www.fda.gov/news-events/press-announcements/fda-announces-first-participant-selected-tempo-digital-health-devices-pilot) | CMS ACCESS model (https://www.cms.gov/priorities/innovation/innovation-models/access)

Federal Health Policy Watch

HHS narrows Title VI liability to intentional discrimination. Effective July 24, HHS removed disparate-impact or effects-based provisions from its Title VI regulations. OCR says it will continue complaint investigations, compliance reviews, and enforcement against intentional race-, color-, or national-origin discrimination, and may still use statistical disparities as evidence of intent.

Policy relevance: This changes HHS’s Title VI enforcement theory for federally funded health care, but it is not a broad nondiscrimination safe harbor. It does not erase Section 1557, Section 504, state law, or other applicable duties.

Physician policy angle: Route the rule to civil-rights and legal colleagues, monitor implementation guidance and litigation, and avoid operational advice that overreads a Title VI amendment into permission under other statutes. HHS announcement (https://www.hhs.gov/press-room/hhs-restores-title-vis-promise-equal-protection.html) | Federal Register rule (https://www.federalregister.gov/documents/2026/07/24/2026-15000/rescinding-portions-of-the-us-department-of-health-and-human-services-title-vi-regulations-to-align)

Congress / Hearings / Oversight

No verified fresh congressional movement earned brief space this morning.

Signal Scan

The cached X scan finished partialwithfindings; one congressional topic timed out. An official ONC post led to the verified USCDI v7 release above. A separate ONC post recirculated the June 30 SVAP action, while independent commentary on CMS clinical-AI payment added interpretation but no new official policy. No other social signal changed the strategic picture.

Policy Action Implications

- Start a targeted USCDI v7-to-v8 review and identify submissions before September 28; focus on implementation readiness, vendor responsibility, test tools, terminology mapping, and ambulatory workflow.

- Engage FDA/CMMI on TEMPO–ACCESS guardrails: physician-led oversight, AI transparency, escalation and liability, data governance, interoperable care updates, and co-management payment adequacy.

- Coordinate a narrow Title VI legal readout and watch OCR implementation; keep the analysis distinct from Section 1557, Section 504, and state-law obligations.